Anticoagulation therapy is mandatory in patients with pulmonary embolism to prevent
significant morbidity and mortality. The mainstay of therapy has been vitamin‐K antagonist …

Four non-vitamin K antagonist oral anticoagulants (NOACs) have now been evaluated in
clinical trials, providing new therapeutic options for the treatment of venous …

Four target-specific oral anticoagulants (TSOA's) have been compared to a vitamin K
antagonist for the treatment of acute venous thromboembolism (VTE): dabigatran (D) …

Background Patients with venous thromboembolism (VTE) often have comorbidities that
require use of antiplatelets. However, evidence on the effects of concomitant use of direct …

Background Novel oral anticoagulants are approved in several indications: rivaroxaban,
apixaban, and dabigatran for the prevention of venous thromboembolism after elective hip …

New oral anticoagulants (NOACs) may represent an alternative to standard therapy with
vitamin K antagonists (VKA). However, up to the present, it is unknown whether these drugs …

In Western countries, venous thromboembolism (VTE) is a widespread and serious disorder,
with hospital admission rates that appear to be increasing. Current anticoagulant therapies …

Direct oral anticoagulants (DOACs) have become the recommended first choice
anticoagulant agent for treatment of acute venous thromboembolism (VTE) in non-cancer …

Background Several novel oral anticoagulants have been studied for the prevention and
treatment of venous thromboembolism (VTE) in different patient populations. Clinicians will …

Vitamin K antagonists (VKA) and heparins have been utilized for the prevention and
treatment of thromboembolism (arterial and venous) for decades. Targeting and inhibiting …